EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 345 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are... September 30, 2019 Two-Time Breast Cancer Warrior Left Devastated After Package Full of Meds... June 25, 2020 Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... April 6, 2021 Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... July 6, 2022 Load more HOT NEWS How we can reduce cancer risk in inflammatory bowel disease patients... Dealing With Fears Zucchini everywhere Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among...
